KRAS Variant Enhances Kinase Target Engagement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing kinase ligands have difficulty targeting and engaging certain kinases effectively, despite improved specificity.
Innovation Solution
The co-expression of kinases with an active variant of KRAS enhances the engagement of kinases by kinase binding agents, utilizing functional kinase binding agents that include a kinase binding moiety and a functional element.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If kinase ligands are designed with improved specificity, then binding selectivity increases, but target engagement effectiveness decreases
Solution Approach 1:
The patent introduces an active KRAS variant as an intermediary component that works in combination with kinase binding agents to enhance target engagement. The KRAS variant acts as a mediator that facilitates the interaction between the binding agent and the kinase target, thereby improving engagement effectiveness while maintaining the specificity of the original ligand design.
2Device complexity
If kinase binding agents are used alone, then simplicity of the system is maintained, but detection and quantification capability is insufficient
Solution Approach 1:
The patent combines kinase binding agents with active KRAS variants to create a hybrid system that achieves enhanced detection and quantification capabilities. By merging these two components, the system accomplishes improved measurement precision without introducing excessive complexity, as the KRAS variant integrates seamlessly with the existing binding agent framework.
Data Source
AI summary
Provided herein are systems and methods for enhanced engagement of protein kinases by kinase binding agents. In particular, the engagement of kinases by functional kinase binding agents is enhanced by the co-expression of the kinases with an active variant of KRAS.